Back to search results

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Abroad (travel likely)RecruitingPHASE2

Conditions

Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia

    Contact: Study coordinator (Sara Wahlroos) · sara.wahlroos@lh.org.au · 0285140362
    Contact: Principal Investigator (Sara Wahlroos)

  • Monash Medical Centre, Clayton, New South Wales, Australia

    Contact: Study coordinator (Marion Harris) · marion.harris@monashhealth.org · 0385722392
    Contact: Principal Investigator (Marion Harris)

  • Royal North Shore Hospital, St Leonards, New South Wales, Australia

    Contact: Study coordinator (Sally McCowatt) · sally.mccowatt@health.nsw.gov.au · 02 9463 1181

  • Westmead Hospital, Westmead, New South Wales, Australia

    Contact: Study coordinator (Adnan Nagrial) · Adnan.Nagrial@health.nsw.gov.au · 0288905200
    Contact: Principal Investigator (Adnan Nagrial)

  • Wollongong and Shoalhaven District Memorial Hospital, Wollongong, New South Wales, Australia

    Contact: Study coordinator (Lorraine Chantrill) · Lorraine.chantrill@health.nsw.gov.au · 0242225260
    Contact: Principal Investigator (Lorraine Chantrill)

  • Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

    Contact: Study coordinator (Laura Tam) · laura.tam@austin.org.au · 0734438050
    Contact: Principal Investigator (Laura Tam)

  • Flinders Medical Centre, Bedford Park, South Australia, Australia

    Contact: Study coordinator (Amitesh Roy) · amitesh.roy@sa.gov.au · 0882048997
    Contact: Principal Investigator (Amitesh Roy)

  • Austin Health, Melbourne, Victoria, Australia

    Contact: Study coordinator (Niall Tebbutt) · niall.tebbutt@austin.org.au · 0394965763
    Contact: Principal Investigator (Niall Tebbutt)
View source on ClinicalTrials.gov(opens in a new tab)